WOBURN, Mass.--(BUSINESS WIRE)--BioProcess Technology Consultants Inc. (BPTC), the leading provider of CMC services to the global biopharmaceutical industry, is pleased to announce the promotion of Patricia Seymour, MBA and Sheila Magil, Ph.D., to the positions of Principal Consultant effective March 1, 2018. In their new roles, Ms. Seymour and Dr. Magil will take on the additional responsibilities of managing client engagements and supervising staff while continuing to provide consulting services to clients. As Senior Consultants at BPTC for over ten years, both Patti and Sheila have assisted many companies with their product development and commercialization activities.
“Patti has developed an outstanding reputation throughout the biopharmaceutical industry, leading teams of consultants in delivering the highest quality services to our clients,” said Howard L. Levine, Ph.D., president and CEO of BPTC. “In her new role as Principal Consultant, Patti will take on additional internal management and project oversight responsibilities and will continue to serve as an Executive Sponsor managing the business relationships with the Company’s clients.”
Commenting on Dr. Magil’s contributions, Dr. Levine added, “In addition to continuing her role as a subject matter expert to our clients in the quality, regulatory, and analytical areas, Sheila also serves as an Executive Sponsor managing client relationships and will now take on the added role of overseeing BPTC’s Human Resource and Administration functions. In this role, Sheila will support the Company’s senior management team as we continue to grow and expand our consulting services.”
About BioProcess Technology Consultants
Founded in 1994, BPTC is the recognized worldwide leader in biologics CMC consulting, providing a full range of technical, regulatory, and strategic assistance to pharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The company works with clients globally to find and apply solutions to the challenges of biopharmaceutical product development from clone to commercial®. BPTC helps develop manufacturing processes and strategies that enhance the overall value of client companies, de-risk biopharmaceutical development, and accelerate the advancement of new products from clone to clinic®. BPTC also helps investors, service providers, and companies make informed decisions by providing technical due diligence services and business evaluations of new products as well as technologies for product discovery, development, or commercialization. For more information about BPTC, visit http://www.bptc.com. Follow us on Twitter at @bptcglobal or LinkedIn at http://www.linkedin.com/company/bioprocess-technology-consultants-inc.
